Role of flavin-containing monooxgenase in drug development
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
This review summarizes some recent observations and information related to the role of the flavin-containing monooxygenase (FMO) in preclinical drug development. Flavin-containing monooxygenase is a complimentary enzyme system to the cytochrome P450 (CYP) family of enzymes and oxygenates several soft, highly polarizable nucleophilic heteroatom-containing chemicals and drugs. The products of FMO-mediated metabolism are generally benign and highly polar, readily excreted materials. There may be some advantages in designing drugs that are metabolized in part by FMO and not exclusively by CYP. In this review, I describe the practical aspects for the participation of FMO in drug and chemical metabolism including: i) the study of FMO using in vitro preparations; ii) some observations about metabolism of drugs and chemicals by FMO in vivo; and iii) the consequences of studying FMO-related metabolism in various small animal models. Some of the preclinical research and development areas related to FMO are not fully mature areas and there are certain gaps in our knowledge. However, I include discussion of these areas to stimulate further work and invite further discussion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression
Koukouritaki, S. B., Simpson, P., Yeung, C. K., Rettie, A. E., & Hines, R. N. (2002) · Pediatric Research · doi:10.1203/00006450-200202000-00018 · Cited by 245
Cashman, J., Camp, K., Fakharzadeh, S., Fennessey, P., Hines, R., Mamer, O., Mitchell, S., Preti, G., Schlenk, D., & Smith, R. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489505 · Cited by 110 · cited 1×
“Unlike the oxidative portion of the half reaction, where it is clear that FMO3 is solely responsible for formation of TMA N-oxide, the nature of the catalyst(s) that forms the retro-reduction product TMA is unknown [42] .”
BackgroundSelf-citation
Cited by
The contributory role of gut microbiota in cardiovascular disease
Tang, W. H. W., & Hazen, S. L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72331 · Cited by 641
The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance
Warrier, M., Shih, D. M., Burrows, A. C., Ferguson, D., Gromovsky, A. D., Brown, A. L., Marshall, S., McDaniel, A., Schugar, R. C., Wang, Z., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.036 · Cited by 414
“Balance in a Gut Microbe-Dependent Fashion FMO3 has many potential endogenous and xenobiotic substrates (Cashman and Zhang, 2006; Cashman 2008) that could be involved in its ability to regulate cholesterol balance and inflammation.”
Fennema, D., Phillips, I. R., & Shephard, E. A. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070615 · Cited by 355
Metaorganismal nutrient metabolism as a basis of cardiovascular disease
Brown, J. M., & Hazen, S. L. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000036 · Cited by 80
Metadata
- Authors
- Cashman, J. R.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2008-11-12
- Volume
- 4
- Issue
- 12
- Pages
- 1507-1521
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W1994057917
- Cited by
- 79
- References
- 2
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of flavin-containing monooxgenase in drug development. https://app.cochat.ai/papers/10.1517/17425250802522188
- The paper
- Cashman, J. R. (2008). Role of flavin-containing monooxgenase in drug development. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425250802522188
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.